PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.

ABSTRACT: Prostate cancer (PCa) is the second most common malignancy among men in the world. Castration-resistant prostate cancer (CRPC) is the lethal form of the disease, which develops upon resistance to first line androgen deprivation therapy (ADT). Emerging evidence demonstrates a key role for the PI3K-AKT-mTOR signaling axis in the development and maintenance of CRPC. This pathway, which is deregulated in the majority of advanced PCas, serves as a critical nexus for the integration of growth signals with downstream cellular processes such as protein synthesis, proliferation, survival, metabolism and differentiation, thus providing mechanisms for cancer cells to overcome the stress associated with androgen deprivation. Furthermore, preclinical studies have elucidated a direct connection between

SUBMITTER: Edlind MP 

PROVIDER: S-EPMC4023363 | biostudies-literature | 2014 May-Jun

REPOSITORIES: biostudies-literature